The AJMC® Chronic Kidney Disease compendium is a comprehensive resource for clinical news and expert insights on the condition and treatment of loss of kidney function.
March 28th 2024
The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
CMS Finalizes Policy to Improve Kidney Care for Low-Income Medicare Patients
November 3rd 2021To help close health equity gaps, CMS finalized a rule that will update payment rates and improve incentives for providers to encourage them to increase access to home dialysis and kidney transplants for low-income patients with end-stage renal disease.
Read More
Remove Race From Equation Used to Assess Kidney Function, Researchers Say
September 23rd 2021Long-awaited reports released Thursday call for eliminating race in estimated glomerular filtration rate equations and point to alternatives in an effort to eliminate disparities in chronic kidney disease.
Read More
Il-6 Levels, CKD Status Could Identify Patients Needing Anti-Inflammatory Treatment
August 28th 2021Research shows higher levels of interleukin 6 in patients with chronic coronary syndrome were associated with an increased risk of cardiovascular events in patients with chronic kidney disease.
Read More
Nephrotic Syndrome Linked With End-Stage Kidney Disease, Cardiovascular Issues
August 13th 2021Patients with nephrotic syndrome were far more likely than healthy controls to suffer end-stage kidney disease, particularly if they had focal segmental glomerulosclerosis or membranous nephropathy.
Read More
Panel Recommends 5 Reporting Requirements for Standardizing AKI Definition
July 20th 2021Inconsistent application and measure of the Kidney Disease Improving Global Outcomes definition of acute kidney injury (AKI) prompted this review, which used a measure of 75% agreement when defining consensus.
Read More
CMS Targets Health Care Disparities in ESRD Rulemaking for 2022
July 2nd 2021The proposed changes to the payment model for end stage renal disease (ESRD) would make it the first payment model under the CMS Innovation Center to directly address health equity by incentivizing increased rates of home dialysis and kidney transplants.
Read More
Beyond Diabetes: SGLT2 Inhibitors in Heart Failure, CKD, and in Combination With GLP-1 RAs
June 27th 2021How therapeutic advances can address all 3 conditions was the topic of a symposium Friday during the 81st Scientific Sessions of the American Diabetes Association (ADA), “The Intersection of Diabetes, Heart Failure and Kidney Disease: Challenges and New Insights.”
Read More
Many Patients With ESKD Are Not Placed on Kidney Transplant Waitlist Despite Eligibility
June 17th 2021Eligible patients who are not waitlisted for kidney transplants lose profound opportunities and are subject to racial and socioeconomic disparities regarding waitlist placement, a study showed.
Read More
Contributor: It’s Time for Medicare to Cover Oral Alternative Therapies for Iron Deficiency Anemia
June 6th 2021The founder of the Renal Support Network discusses why patients with chronic kidney disease want Congress to change Medicare policy to allow payment for oral treatments for anemia caused by iron deficiency.
Read More
Longer Dialysis, Lack of Transplant Among Risk Factors for Vascular Disease in Children With ESRD
June 2nd 2021About 5.4% of patients with end-stage renal disease (ESRD) who begin renal replacement therapy as children go on to have vascular events, and 4.1% of those patients die as a result of vascular events, though the real incidence rates are likely higher, according to new research.
Read More
Study: Metformin Effective for Many Patients With T2D, Chronic Kidney Disease
May 28th 2021Some consider patients with type 2 diabetes (T2D) and chronic kidney disease poor candidates for metformin monotherapy due to the risk of lactic acidosis. However, new research finds patients who can tolerate the drug can gain similar benefits with or without kidney disease.
Read More